Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
(NASDAQ: ARQT) Delayed: 26.66 +0.45 (1.72%)
Previous Close $26.21    52 Week High $ 
Open $26.42    52 Week Low $ 
Day High $27.17    P/E N/A 
Day Low $26.24    EPS $ 
Volume 1,528,828       

(NASDAQ: ARQT) Delayed: 26.66 +0.45 (1.72%)
Previous Close $26.21    52 Week High $ 
Open $26.42    52 Week Low $ 
Day High $27.17    P/E N/A 
Day Low $26.24    EPS $ 
Volume 1,528,828